Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%

Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its popular obesity injection, Wegovy (semaglutide), at a discounted price of $499 per month to patients who do not have insurance coverage and pay by cash. The offer is also available to patients with insurance coverage who do not have coverage for obesity medicines. The website provides an option for these patients to have their injections delivered to their homes.

Wegovy is currently priced at around $1,350 per month. However, most patients with coverage pay much less, around $0 to $25 a month.

NVO’s stock rose almost 4% in response to the news, as this new effort will make Wegovy cheaper and easier to access.

However, the stock has plunged 33.1% in the past year compared with a decrease of 2.5% for the industry.

The discounted prices come on the heels of the FDA’s announcement in late February that the shortage of Wegovy is resolved and the medicine is no longer in short supply.

NVO’s Announcement Follows A Similar Move by LLY

Novo Nordisk’s announcement follows a similar move by rival Eli Lilly LLY. Last week, Lilly also announced that it is reducing the prices of its 7.5 mg and 10 mg single-dose vials of obesity treatment Zepbound to $499 per month for customers paying through a new self-pay program called LillyDirect Self-Pay Pharmacy Solutions. The 7.5 mg and 10 mg vials are currently priced at $599 and $699, respectively. Prices of 2.5 mg and 5 mg vials are also being reduced to $349 and $499 per month, respectively.

The FDA removed Lilly’s GLP-1 products, Mounjaro and Zepbound (tirzepatide), from its shortage list in December 2024 after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.

Stocks of HIMS and LFMD Hit Hard

Novo Nordisk and Lilly’s semaglutide and tirzepatide medicines, respectively, were added to the FDA’s shortage list in 2022 due to supply shortages. Upon placement of a drug under the FDA’s shortage list, compounding pharmacies are allowed to produce copies of the approved drug to meet existing demand. Compounded drugs are, however, not approved by the FDA.

The launch of cheaper versions of NVO and LLY’s obesity treatments and their removal from the FDA’s shortage list have dealt a blow to shares of telehealth companies like LifeMD LFMD and Hims & Hers Health HIMS.

LifeMD and Hims & Hers Health offer lower-cost compounded versions of weight-loss drugs at their pharmacies during a shortage. However, with both semaglutide and tirzepatide removed from the shortage lists, LifeMD and Hims & Hers Health will have to stop selling the compounded drugs. Stocks of LifeMD and Hims & Hers Health have plunged more than 30% since the FDA removed Wegovy from the shortage list in late February.

Novo Nordisk currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Novo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

LifeMD, Inc. (LFMD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research